IL-2 Combination Therapy Development Services
Creative Biolabs' IL-2 combination therapy development services provide comprehensive preclinical support, covering everything from the molecular validation of novel IL-2 muteins to the translational optimization of combination regimens. We provide high-resolution functional data that confirms selective T-cell activation and synergistic efficacy, particularly targeting the durable Tpex population. Clients gain a data-driven, de-risked developmental strategy and a complete preclinical data package, significantly accelerating the path of their IL-2 agent from discovery into advanced in vivo validation with a superior therapeutic index.
Introduction What We Can Offer Types of Our Services Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us
Introduction of IL-2 Combination Therapy Development Services
Interleukin-2 (IL-2) is a powerful cytokine for drug development, but systemic toxicity and indiscriminate activation of immunosuppressive regulatory T cells (Tregs) limit its utility. The modern field has evolved to engineered IL-2 muteins designed to preferentially signal through the intermediate-affinity receptor (CD122/CD132), thereby avoiding CD25-mediated Treg activation. Success hinges on rational combination strategies (e.g., with immune checkpoint inhibitor (ICIs) mechanisms or targeted immunocytokines) to achieve superior effector cell expansion, overcome the immunosuppressive tumor microenvironment (TME), and ensure a manageable toxicity profile in preclinical models.
Discover how we can help, request a consultation.
Fig.1 The combined mechanism of P-IL-2 and CDK4/6 inhibitors. 1
What We Can Offer
Customized IL-2 Mutein Screening and Engineering
We provide fully flexible IL-2 agent functional validation, allowing for personalized assay design to precisely characterize novel IL-2 muteins, Fc-fusions, and immunocytokines for your specific target receptors and affinity constants.
Translational PK/PD Modeling in HuMice
We integrate comprehensive PK and PD data generated in our highly predictive humanized mouse models (HuMice) to accurately simulate human biological scenarios, leading to an optimal, de-risked dose and schedule recommendation for further preclinical development.
Optimized Synergy Assessment for Multiple Partners
Our customized in vitro co-culture and in vivo combination modules allow you to simultaneously screen for synergistic effects with various partners, including ICIs, ADCC-mediating antibodies, and targeted small molecule inhibitors, providing a data-driven path to the best combination regimen.
Guaranteed CD25 Avoidance Validation
Our primary focus is safety. We employ high-resolution competitive SPR/ BLI and pSTAT5 assays to empirically confirm that your agent minimizes binding to the α-subunit (CD25) of the IL-2 receptor, thereby mitigating the risk of systemic toxicity and Treg activation.
IL-2 Combination Therapy Development Services at Creative Biolabs
IL-2 & ICI Combination Therapy Development
This service focuses on modeling the synergy between your IL-2 agent and PD-1/PD-L1 or CTLA-4 blockade. We aim to confirm that IL-2 acts synergistically to revitalize the exhausted T-cell pool (Tpex) and acts effectively in models that reflect reduced responsiveness to prior ICI treatment. We validate the optimal schedule to maximize the anti-exhaustion effect (e.g., reducing TOX expression) while minimizing peripheral toxicity.
Learn More →
IL-2 & Antitumor Antibody Combination Therapy Development
This module specializes in non-ICI antibody combinations, including targeted Immunocytokines and ADCC-competent antibodies. We specifically model how the IL-2 component can amplify the ADCC activity of the partner antibody by expanding and activating the NK cell compartment and cytotoxic T cells. The service includes stability and release kinetics analysis for targeted IL-2 fusions.
Learn More →
Why Choose Us?
|
Key Advantages
|
Unique Features
|
|
Tpex-Centric Optimization
|
Our screening protocols are centered on the stem-like CD8 T cell (Tpex) population, ensuring your combination fuels the long-term, self-renewing engine of anti-tumor immunity, not just transient peripheral expansion.
|
|
Expertise in Targeted Delivery Platforms
|
We possess deep knowledge in optimizing novel formats like immunocytokines and cis-targeting strategies (e.g., PD1-IL2v fusions), which provide the essential IL-2 signal directly to PD-1+ exhausted T-cells in the TME.
|
|
Validated Success with CD25 Avoidance
|
We utilize advanced mutational analysis, grounded in the successful design principles of agents like CEA-IL2v, to guarantee CD25 binding is abolished, preventing peripheral Treg activation and mitigating systemic toxicity.
|
To fully understand the Creative Biolabs advantage, we invite you to get a quote today.
Customer Reviews
-
High Selectivity for Effector Cells
Using Creative Biolabs' services in our research has significantly improved the confidence in our IL-2 mutein's therapeutic window. The functional Tpex profiling confirmed a fourfold selective STAT5 activation in CD8+ T cells over Tregs, which was critical for moving past the preclinical stage. - Dr. J. F****r.
-
Predictive In Vivo Data
Creative Biolabs' services facilitated the identification of an optimal IL-2/ADCC antibody ratio. Their HuMice data were remarkably predictive, showing the combination increased intratumoral CD8+: Treg ratio from 2:1 to ~ 8:1. This synergistic T-cell skewing completely validated our translational hypothesis. - Prof. L. M***s.
FAQs
Q: How does your service ensure our IL-2 mutein avoids activating immunosuppressive Tregs?
A: We go beyond standard binding assays. Our core strategy involves abolishing CD25 binding and then validating the resulting selectivity with functional pSTAT5 profiling in a mixed CD8+ T-cell and Treg population. This two-part process confirms the IL-2 signal is strongly biased toward effector cells (CD122/CD132) to ensure safety.
Q: Why do I need combination therapy development if my IL-2 mutein already shows high selectivity?
A: While high selectivity is essential for safety, monotherapy often fails to overcome the highly immunosuppressive nature of the TME. A rational combination, such as with a CDK4/6 inhibitor (to deplete Tregs) or an immunocytokine (for localized delivery), is required to achieve durable, complete tumor regression by addressing multiple inhibitory pathways simultaneously.
Related Services
Immunocytokine Engineering Development
This specialized service focuses on the rational design and construction of next-generation IL-2 immunocytokines. We offer expert guidance on selecting optimal antibody-cytokine formats, linker chemistry, and fusion sites to maximize tumor targeting specificity and minimize non-specific IL-2 release.
Learn More →
Human PBMC-T Mouse Model
This core service supports our predictive PK/PD integration by offering tailored HuMice platforms. We specialize in customizing the human immune cell engraftment protocol and establishing tumor models that are optimally configured for evaluating the efficacy and safety of your IL-2 combination agent.
Learn More →
How to Contact Us
Creative Biolabs de-risks your pipeline and provides a complete preclinical data package that maximizes the potential for synergy and success by focusing on Tpex activation, CD25 avoidance, and predictive PK/PD modeling in humanized systems. Ready to transform your IL-2 agent into a market-leading combination strategy? Contact our team for more information and to discuss your project.
Reference
-
Wang, Di et al. "The combination of IL-2 nanoparticles and Palbociclib enhances the anti-tumor immune response for colon cancer therapy." Frontiers in immunology vol. 15 1309509. 30 Jan. 2024.1309509 Distributed under an Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2024.1309509
For Research Use Only | Not For Clinical Use
